Drug Discovery World

FEBRUARY 5, 2024

Brian Gladsden, CEO, Mosaic Therapeutics “The industry has already made tremendous strides in targeted drug discovery in oncology, particularly as the industry moves further away from simply looking at tumour histology and relying more on cancer gene sequencing. In the past 10 years, immunotherapy trials have increased by 430%.

Research 116

Research Drug Delivery Systems Gene Sequencing Trials 116

pharmaphorum

JUNE 23, 2022

The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis. billion in potential milestones if the project advances through development and onto the market.

Gene Editing 86

Gene Editing In-Vivo Gene Sequencing Gene 86

pharmaphorum

MARCH 10, 2022

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials.

Genetics 98

Genetics Gene Sequencing Gene Clinical Trials 98

pharmaphorum

SEPTEMBER 14, 2022

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). The current schedule is for trials to start in 2024, with first safety and efficacy data coming a year later.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

Drug Discovery World

DECEMBER 13, 2022

Researchers participating in the CRDC have uncovered novel mutations, are developing targeted therapies and are matching patients with innovative clinical trials. . As causative variants are identified by CRDC researchers, results are returned to participants.

Genetics 52

Genetics Research Genome Genomics 52

Drug Discovery World

MARCH 27, 2023

The UK government endorses TREs, having recently announced an investment package of up to £200 million in TREs and digitally enabled clinical trials 4. TREs are already paving the way to greater collaboration in drug development, improvements to existing treatment approaches, and driving better patient outcomes.

Genome 52

Genome Genomics Research Scientist 52